Georgetown Lombardi Comprehensive Cancer Center | Strategic Alliance Partners

May 19, 2023

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

May 19, 2023

Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

May 12, 2023

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

May 09, 2023

John L. Marshall, MD, discusses the identification of targetable subsets of patients with advanced CRC, unmet needs that remain to be addressed for patients with advanced CRC, and the continued need for a multidisciplinary approach in treating patients across the gastrointestinal cancer spectrum.

May 05, 2023

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

May 05, 2023

Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.

April 28, 2023

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

April 14, 2023

Stephen V. Liu, MD, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer.

April 06, 2023

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

February 07, 2023

Stephen V. Liu, MD, discusses the future of MET-targeted agents in non–small cell lung cancer based on the FDA breakthrough designation for telisotuzumab vedotin.

December 18, 2022

Stephen V. Liu, MD, discusses the effect of the FDA approval of atezolizumab on the development of other chemoimmunotherapy regimens and ongoing efforts to expand and individualize treatment options in small cell lung cancer.

December 09, 2022

The addition of cemiplimab and REGN3767 to paclitaxel improved pathologic complete response vs paclitaxel alone in patients with triple-negative and hormone receptor–positive, HER2-negative breast cancer, according to data from the phase 2 I-SPY2 trial.

December 02, 2022

Stephen V. Liu, MD, highlights the advantages of antibody-drug conjugates in lung cancer treatment, the current landscape of antibody-drug conjugate development, and several questions and considerations for continued investigation.

November 29, 2022

Stephen V. Liu, MD, discusses efforts to develop atezolizumab-based combination therapies for patients with small cell lung cancer.

November 18, 2022

OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, have recognized 4 gastrointestinal physician-scientists and a prominent patient advocate, naming them as 2022 Luminary Awards in GI Cancers.

October 13, 2022

John L. Marshall, MD, provides an overview of esophageal squamous cell carcinoma and discusses several key updates to the treatment landscape, including putting data in the context of the treatment algorithm.

October 11, 2022

Findings from the DREAMseq trial indicate that nivolumab plus ipilimumab should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.

October 05, 2022

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

August 19, 2022

Stephen V. Liu, MD and Neal E. Ready, MD, PhD, discuss the new data with nivolumab plus ipilimumab in treatment-naïve NSCLC and provide commentary on treatment considerations for patients who are eligible to receive these regimens.

June 30, 2022

The addition of durvalumab to gemcitabine and cisplatin demonstrated an improvement in overall survival vs gemcitabine and cisplatin plus placebo as frontline therapy in patients with advanced biliary tract cancer, regardless of primary tumor location.